CA-GSD/ANANDA
23.3.2021 16:02:07 CET | Business Wire | Press release
POSITIVE ALL THE WAY , an award-winning documentary about the Paralympics is now available internationally through Ananda Media. The short documentary, produced by The Foundation for Global Sports Development (GSD) and Sidewinder Films, won “Best Documentary” at the Together! 2020 Disability Film Festival .
With personal interviews and captivating footage, POSITIVE ALL THE WAY celebrates the power of adaptive sport to ignite the human spirit. The film chronicles the growth of the Paralympics under the leadership of Sir Philip Craven, who served as the President of the International Paralympic Committee from 2001 through 2017. Staying true to the integrity of sport and his personal principles, Sir Philip led the sports organization through moments of crisis – such as funding shortfalls and the 2016 Russian doping scandal - while positioning the Paralympics as a leading sports organization.
"Ever since I first met Steven Ungerleider and David Ulich in 2011, I very quickly realized that the true spirit of sport is embodied in everything that The Foundation for Global Sports Development and Sidewinder Films undertakes,” said Sir Philip Craven, who is featured in the film. “In my work with the International Paralympic Committee, I tried to follow that principle and to also follow very closely the vision of the IPC which was ’to enable Para athletes to achieve sporting excellence and inspire and excite the world.’ This is what I believe Sidewinder Films portrays in POSITIVE ALL THE WAY , and I am so pleased that they have partnered with Ananda Media in order that many more people can experience the true spirit of sport!”
"The Paralympic movement reaches across the globe and plays a remarkable role in promoting inclusion worldwide,” said David Ulich, director and producer of the film. “We are delighted to partner with Ananda Media to bring POSITIVE ALL THE WAY to international audiences who can join this movement.”
Dr. Steven Ungerleider, director and producer of POSITIVE ALL THE WAY, agreed. “Sport has the power to change the world, and we are passionate about telling those stories through film. Working with Ananda Media is a perfect fit, and we are honored to have our documentary featured alongside other compelling sports films.”
Ananda Media is a French-based distributor of adventure sports, travel, and healthy lifestyle content. Much of their content, including POSITIVE ALL THE WAY , is available on-demand for worldwide audiences. Visit http://anandamedia.net to learn more.
About Ananda Media
Ananda Media is a producer and distributor of action sports and adventure travel programming for television and digital media. We pride ourselves on working with the top independent film-makers, and TV Channels in order to ensure that our content offering is both unparalleled and broadcast, streamed or downloaded to millions around the world.
More info: http://anandamedia.net
About The Foundation for Global Sports Development and Sidewinder Films
The Foundation for Global Sports Development, established in 1996, was born out of a desire to promote and protect the best parts of sport. Guided by its original mission, the foundation delivers and supports initiatives that promote accessible, fair, and abuse-free sport for youth. The foundation achieves this objective through grants, awards, educational projects, and filmmaking. In 2015, the foundation launched its media company, Sidewinder Films, to inspire and educate audiences through films that shed light on the remarkable, untold stories that celebrate the sport of life. Visit www.globalsportsdevelopment.org and www.sidewinderfilms.org to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005297/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom